JP2008526988A - キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素 - Google Patents

キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素 Download PDF

Info

Publication number
JP2008526988A
JP2008526988A JP2007551409A JP2007551409A JP2008526988A JP 2008526988 A JP2008526988 A JP 2008526988A JP 2007551409 A JP2007551409 A JP 2007551409A JP 2007551409 A JP2007551409 A JP 2007551409A JP 2008526988 A JP2008526988 A JP 2008526988A
Authority
JP
Japan
Prior art keywords
ylmethyl
indol
pyridin
urea
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007551409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526988A5 (cg-RX-API-DMAC7.html
Inventor
エー. ミッチェル,スコット
ダイアナ ダンカ,ミハエラ
エー. ブロムグレン,ピーター
ダブリュ. デジモーン,ロバート
エー.アイ. ピッピン,ダグラス
アール. ブリッテリ,デイヴィッド
Original Assignee
シージーアイ ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージーアイ ファーマシューティカルズ,インコーポレーテッド filed Critical シージーアイ ファーマシューティカルズ,インコーポレーテッド
Publication of JP2008526988A publication Critical patent/JP2008526988A/ja
Publication of JP2008526988A5 publication Critical patent/JP2008526988A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
JP2007551409A 2005-01-14 2006-01-13 キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素 Pending JP2008526988A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64388605P 2005-01-14 2005-01-14
US73299905P 2005-11-02 2005-11-02
PCT/US2006/001272 WO2006076593A1 (en) 2005-01-14 2006-01-13 1,3-diaryl substituted ureas as modulators of kinase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012208429A Division JP2013028628A (ja) 2005-01-14 2012-09-21 キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素

Publications (2)

Publication Number Publication Date
JP2008526988A true JP2008526988A (ja) 2008-07-24
JP2008526988A5 JP2008526988A5 (cg-RX-API-DMAC7.html) 2010-12-16

Family

ID=36250833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007551409A Pending JP2008526988A (ja) 2005-01-14 2006-01-13 キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素
JP2012208429A Pending JP2013028628A (ja) 2005-01-14 2012-09-21 キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012208429A Pending JP2013028628A (ja) 2005-01-14 2012-09-21 キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素

Country Status (13)

Country Link
US (1) US20060199846A1 (cg-RX-API-DMAC7.html)
EP (2) EP2397478A1 (cg-RX-API-DMAC7.html)
JP (2) JP2008526988A (cg-RX-API-DMAC7.html)
KR (1) KR101292598B1 (cg-RX-API-DMAC7.html)
CN (1) CN102267978A (cg-RX-API-DMAC7.html)
AU (1) AU2006204790B2 (cg-RX-API-DMAC7.html)
CA (1) CA2594449A1 (cg-RX-API-DMAC7.html)
ES (1) ES2393741T3 (cg-RX-API-DMAC7.html)
IL (1) IL184494A (cg-RX-API-DMAC7.html)
NZ (1) NZ556433A (cg-RX-API-DMAC7.html)
RU (1) RU2402544C2 (cg-RX-API-DMAC7.html)
TW (1) TWI378925B (cg-RX-API-DMAC7.html)
WO (1) WO2006076593A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013028628A (ja) * 2005-01-14 2013-02-07 Cgi Pharmaceuticals Inc キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素
JP2017516778A (ja) * 2014-05-28 2017-06-22 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
JP2022536755A (ja) * 2019-06-14 2022-08-18 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
JP5236499B2 (ja) * 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
JP2011520809A (ja) * 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
AU2010289143A1 (en) * 2009-08-24 2012-02-16 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
CN103288684B (zh) * 2013-05-03 2014-12-10 西安交通大学 一种具有抗肿瘤活性的联苯脲化合物及其制备方法
CN104725319A (zh) * 2015-03-11 2015-06-24 西安交通大学 一种具有抗肿瘤活性的1h-吲唑-3-氨基联苯脲类化合物及其制备方法和应用
CN113527254B (zh) * 2021-07-07 2022-05-03 北京华氏信华科生物科技有限公司 7-甲氧基-1h-吲哚类化合物、制备方法、药物组合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040673A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Novel urea- and thiourea-type compounds
JP2001526220A (ja) * 1997-12-22 2001-12-18 バイエル コーポレイション 置換複素環式尿素を用いたrafキナーゼの阻害
JP2001526258A (ja) * 1997-12-22 2001-12-18 バイエル コーポレイション 対称および非対称置換ジフェニル尿素を用いるrafキナーゼの阻害
WO2003014090A1 (en) * 2001-08-07 2003-02-20 Pharmacia Italia S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003087087A2 (en) * 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE447653B (sv) * 1978-11-14 1986-12-01 Eisai Co Ltd Imidazolderivat samt farmaceutisk komposition innehallande sadant derivat
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
EP0630373A1 (en) * 1992-03-12 1994-12-28 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
DE4327027A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) * 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US6858577B1 (en) * 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US6627647B1 (en) * 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
TWI323658B (en) * 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
BR0309398A (pt) * 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase
AU2003270489A1 (en) * 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
JP4799864B2 (ja) * 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
KR20060010709A (ko) * 2002-09-23 2006-02-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진
US7189723B2 (en) * 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) * 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005019220A2 (en) * 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005047290A2 (en) * 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
ES2465469T3 (es) * 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
EP2397478A1 (en) * 2005-01-14 2011-12-21 CGI Pharmaceuticals, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity.
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040673A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Novel urea- and thiourea-type compounds
JP2001526220A (ja) * 1997-12-22 2001-12-18 バイエル コーポレイション 置換複素環式尿素を用いたrafキナーゼの阻害
JP2001526258A (ja) * 1997-12-22 2001-12-18 バイエル コーポレイション 対称および非対称置換ジフェニル尿素を用いるrafキナーゼの阻害
WO2003014090A1 (en) * 2001-08-07 2003-02-20 Pharmacia Italia S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003087087A2 (en) * 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013028628A (ja) * 2005-01-14 2013-02-07 Cgi Pharmaceuticals Inc キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素
JP2017516778A (ja) * 2014-05-28 2017-06-22 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
JP2022536755A (ja) * 2019-06-14 2022-08-18 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
JP2025037981A (ja) * 2019-06-14 2025-03-18 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物

Also Published As

Publication number Publication date
JP2013028628A (ja) 2013-02-07
RU2402544C2 (ru) 2010-10-27
KR101292598B1 (ko) 2013-08-05
TW200639165A (en) 2006-11-16
NZ556433A (en) 2010-10-29
CN102267978A (zh) 2011-12-07
EP2397478A1 (en) 2011-12-21
EP1858879A1 (en) 2007-11-28
AU2006204790A1 (en) 2006-07-20
IL184494A (en) 2013-04-30
AU2006204790B2 (en) 2012-08-23
KR20070113200A (ko) 2007-11-28
TWI378925B (en) 2012-12-11
EP1858879B1 (en) 2012-06-06
CA2594449A1 (en) 2006-07-20
RU2007130895A (ru) 2009-02-20
US20060199846A1 (en) 2006-09-07
ES2393741T3 (es) 2012-12-27
IL184494A0 (en) 2007-10-31
WO2006076593A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
JP2013028628A (ja) キナーゼ活性モジュレーターとしての1,3−ジアリール置換尿素
EP1858877B1 (en) 1,3 substituted diaryl ureas as modulators of kinase activity
US8222421B2 (en) Certain substituted ureas, as modulators of kinase activity
TWI426908B (zh) 特定化學品、組成物及方法
EP2081923B1 (en) Certain substituted amides, method of making, and method of use thereof
TWI398439B (zh) 特定經取代醯胺、其製法及其用途
JP5715713B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子
TWI316937B (en) Spirocyclic thrombin receptor antagonists
EP3749646B1 (en) Heteroaryl compounds as kinase inhibitor
HUE029370T2 (hu) Rákellenes aktivitású vegyületek
US11046683B2 (en) Activator of TREK (TWIK RElated K+ channels) channels
WO2007081978A2 (en) Modulators of hepatocyte growth factor / c-met activity
EP3423452A1 (en) Wnt signaling pathway inhibitors for treatments of disease
WO2011046991A2 (en) Certain substituted ureas as modulators of kinase activity
JP2005511602A (ja) アントラニル酸アミドおよびvegf受容体チロシンキナーゼ阻害剤としてのその使用
TW201000458A (en) Isoquinolinone derivatives as NK3 antagonists
TWI378095B (en) Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
CN101163691A (zh) 作为激酶活性调节剂的1,3-二芳基取代的脲
HK1114392A (en) 1,3-diaryl substituted ureas as modulators of kinase activity
TW201217336A (en) Chemical compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121108